Pharmacokinetics of a new cephalosporin, CGP 9000 (cefroxadine), in healthy volunteers.
Oral doses of 125, 250, and 500 mg of a new cephalosporin, CGP 9000 (7 beta-[D-2-amino-2-(1,4-cyclohexadienyl)-acetamido]-3-methoxy-ceph-3-em-4-carboxylic acid), given to healthy volunteers, were evaluated pharmacokinetically. The mean peak concentrations with the respective doses were 4.5 +/- 1.4, 7.7 +/- 2.7, and 12.3 +/- 4.2 microgram/ml. The maximum serum concentration occurred after 0.5-1.5 h. The amounts recovered unchanged in urine during 12 h were 96.4 +/- 5.1, 92.4 +/- 11.7 and 96.7 +/- 7.6% of the respective doses. There was straight linear kinetics with a doubling of area under the serum curve for each dose, rising from 6.1 with the lowest, through 12.1 with the middle dose to 23.6 microgram.h/ml with the highest dose. There was an apparent lag of 0.3-0.4 h before absorption. Absorption was relatively rapid, with mean absorption rate constants of 4.68-6.26 h-1. Serum half-life varied between 0.9 and 1.0 h with the different doses. The mean renal clearance values with the three doses ranged between 322 and 344 ml/min.
D000284:Administration, Oral; D000328:Adult; D002511:Cephalosporins / Q000378:metabolism*; D002515:Cephradine / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000378:metabolism*; D004305:Dose-Response Relationship, Drug; D005260:Female; D006801:Humans; D007700:Kinetics; D008297:Male
D002511:Cephalosporins; C012671:cefroxadine; D002515:Cephradine